Analyst Ratings
Here’s a summary of ratings and price targets for Psykey and ResMed from MarketBeat:
| Sell | Hold | Buy | Strong Buy | Rating Score | |
| Psykey | 0 | 0 | 0 | 0 | N/A |
| ResMed | 1 | 5 | 6 | 1 | 2.54 |
ResMed has a target price of $218.18, indicating a potential drop of 9.09%. Analysts view ResMed more favorably than Psykey.
Insider & Institutional Ownership
Institutional investors own 55.0% of ResMed, while insiders hold 1.2%. High institutional ownership suggests confidence in the company’s long-term performance.
Valuation and Earnings
Comparing gross revenue, EPS, and valuation:
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Psykey | N/A | N/A | N/A | ($0.41) | -0.05 |
| ResMed | $4.69B | 7.53 | $1.02B | $6.51 | 36.87 |
ResMed outperforms Psykey in revenue and earnings, though Psykey is currently more affordable based on its P/E ratio.
Profitability
Comparing profitability metrics:
| Net Margins | Return on Equity | Return on Assets | |
| Psykey | N/A | N/A | N/A |
| ResMed | 21.79% | 25.00% | 16.67% |
Summary
ResMed outperforms Psykey in all 11 factors evaluated.
About Psykey
Psykey, Inc. focuses on developing functional products that improve life through entheogenic, adaptogenic, and nootropic ingredients. Founded in 2002 and based in Toronto, Canada, it offers products including functional mushroom coffees and teas.
About ResMed
ResMed Inc. develops medical devices and software for healthcare, focusing on sleep and respiratory care. Founded in 1989 and based in San Diego, California, it offers products for respiratory disorders, including remote monitoring solutions.
Receive News & Ratings for Psykey Daily – Enter your email for a concise daily summary of the latest news and ratings for Psykey and related companies with MarketBeat.com’s FREE daily email newsletter.
`
